Kiel, 11/22/2005 – On November 9, 2005, Proteo Biotech AG at Kiel appointed Birge Bargmann its new President and CEO, after she was already called for such office in its US-American Holding Company, Proteo, Inc. on November 7, 2005.
As a member of the Company's supervisory Board since its foundation in 2000, Birge Bargmann influenced the Company's progress significantly. During this time and before, she contributed substantially to the development of the Company's lead product, i.e. the protease-inhibitor Elafin.
Birge Bargmann will bring into the Company her experience in project management and her profound product knowledge to extend the Company's development potential and to market the Company's products. Already, Birge Bargmann could assure herself of the support and cooperation of well-known scientists and experienced business specialists to achieve her ambitious goals, particularly in establishing strategic alliances nationally and internationally, in bringing forward the further product development, in opening up new fields of application, as well as in marketing and out licensing.
Barbara Kahlke, Ph.D.
Proteo Biotech AG
Am Kiel-Kanal 44
Telephone: +49 431 8888-462
Fax: +49 431 8888-463